Refine by MP, party, committee, province, or result type.

Results 1-15 of 34
Sorted by relevance | Sort by date: newest first / oldest first

May 13th, 2019Committee meeting

Prof. Jane Quinn

Veterans Affairs committee  Your research career would go downhill fairly fast.

May 13th, 2019Committee meeting

Prof. Jane Quinn

Veterans Affairs committee  You would certainly not [Technical difficulty--Editor] funding if you perform in that way.

May 13th, 2019Committee meeting

Prof. Jane Quinn

Veterans Affairs committee  Mefloquine is identified as a causal factor in 15 statements of principles for the Repatriation Medical Authority, which is the basis on which they apply principles through the Department of Veterans' Affairs for treatment and compensation. However, that's not the same as its bei

May 13th, 2019Committee meeting

Prof. Jane Quinn

Veterans Affairs committee  One of the significant steps forward that we've taken here is involving veterans groups in the co-design process that has driven the current neurocognitive health program that's being developed. That absolutely has been done side-by-side with the Department of Veterans' Affairs'

May 13th, 2019Committee meeting

Prof. Jane Quinn

May 13th, 2019Committee meeting

Prof. Jane Quinn

May 13th, 2019Committee meeting

Prof. Jane Quinn

Veterans Affairs committee  I think it's an extremely extraordinary situation and obviously has had significant and lasting ramifications for the Canadian military and all those involved at that time. I think the other point is there is no such thing as informed consent in military populations, and, theref

May 13th, 2019Committee meeting

Prof. Jane Quinn

Veterans Affairs committee  It's becoming a drug that is less and less prescribed by general travel doctors and other general practitioners. I think the international exposure of mefloquine's impact on individuals has caused a significant downturn in its use, but that should really have been driven by the d

May 13th, 2019Committee meeting

Prof. Jane Quinn

Veterans Affairs committee  I'd really just support what Dr. Sellers has said. This is a complex syndrome and there are multiple players coming into that presentation of the clinical symptomology. However, we do know that there are specific liver enzymes that are involved in drug metabolism that would put a

May 13th, 2019Committee meeting

Prof. Jane Quinn

May 13th, 2019Committee meeting

Prof. Jane Quinn

Veterans Affairs committee  That's absolutely the reality for many. Disclosure, particularly the neuropsychiatric side effects related to mefloquine in serving military members, is a black box subject. Certainly my husband experienced that. I know that many of his colleagues who experienced side effects wou

May 13th, 2019Committee meeting

Prof. Jane Quinn

Veterans Affairs committee  Yes, I agree with Dr. Sellers. I think it would be a very unlikely and unusual situation where the need for deployment was so high that the use of mefloquine as a drug of last resort would be advisable or acceptable. The review process would need to occur at least three weeks to

May 13th, 2019Committee meeting

Prof. Jane Quinn

Veterans Affairs committee  Yes, I think it's very clear that mefloquine is fundamentally unsuitable for use in military populations, for many reasons. The immediate discontinuation of oral use of mefloquine across the board should be your first step, acknowledgement of those who have taken the drug and bee

May 13th, 2019Committee meeting

Prof. Jane Quinn

Veterans Affairs committee  I think that has come from a number of places. The first was the very significant impact of the testimony those veterans who have been affected by the experimental drug tafenoquine, and also mefloquine here in Australia, put forward at the Senate inquiry, where it became clear an

May 13th, 2019Committee meeting

Prof. Jane Quinn